



(51) International Patent Classification:

A61M 31/00 (2006.01) A61K 9/20 (2006.01)
A61K 47/34 (2017.01) A61K 9/70 (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:

PCT/US2023/075648

(22) International Filing Date:

29 September 2023 (29.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/377,961 30 September 2022 (30.09.2022) US

(71) Applicant: LYNDRA THERAPEUTICS, INC. [US/US];
65 Grove Street, Suite 301, Watertown, MA 02472 (US).

(72) Inventors: SCRANTON, Richard; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, MA 02472 (US).
NAGARAJ, Nayana; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, MA 02472 (US).

JIANG, Xuemin; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, MA 02472 (US).

(74) Agent: CERPA, Robert, K. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: RISPERIDONE DOSAGE REGIMENS WITH GASTRIC RESIDENCE SYSTEMS




FIG. 3

(57) Abstract: Dosage regimens for gastric residence systems comprising risperidone or a salt thereof are disclosed. The dosage regimens include regimens where immediate release risperidone or a salt thereof is administered during a first period, immediate release risperidone or a salt thereof and gastric residence systems comprising risperidone or a salt thereof are administered during a second period, and gastric residence systems comprising risperidone or a salt thereof are administered over a third period. The dosage regimens also include regimens where immediate release risperidone or a salt thereof and gastric residence systems comprising risperidone or a salt thereof are administered during a co-administration period, and gastric residence systems comprising risperidone or a salt thereof are administered over a subsequent period.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

30 May 2024 (30.05.2024)